{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:06Z","timestamp":1786987026249,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clgc.2026.102570","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:50:13Z","timestamp":1777333813000},"page":"102570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8426-8888","authenticated-orcid":false,"given":"Daniel","family":"Shevrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Sabatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5336-3046","authenticated-orcid":false,"given":"Michael","family":"Akroush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicklas","family":"Pfanzelter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0046-8538","authenticated-orcid":false,"given":"Hussein","family":"Alnajar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Wittich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Helseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clgc.2026.102570_bib0001","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2020.12.039","article-title":"Genomic testing in patients with metastatic castration-resistant prostate cancer: a pragmatic guide for clinicians","volume":"79","author":"Merseburger","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2026.102570_bib0002","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.euo.2023.08.004","article-title":"Practical guidance on establishing a molecular testing pathway for alterations in homologous recombination repair genes in clinical practice for patients with metastatic prostate cancer","volume":"7","author":"Schostak","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2026.102570_bib0003","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO-24-02608","article-title":"Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline","volume":"43","author":"Yu","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102570_bib0004","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate cancer, Version 3.2026, NCCN Clinical Practice Guidelines In Oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2026.102570_bib0005","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor genomic testing for >4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (Olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2026.102570_bib0006","doi-asserted-by":"crossref","first-page":"303","DOI":"10.32074\/1591-951X-1010","article-title":"BRCA testing metastatic castration-resistant prostate cancer: successes and troubles in a real world setting. An Italian multicenter study","volume":"116","author":"Tommasi","year":"2024","journal-title":"Pathologica"},{"key":"10.1016\/j.clgc.2026.102570_bib0007","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1158\/0008-5472.CAN-24-3687","article-title":"Divergent clonal evolution and early dissemination promote genetic heterogeneity of metastases in castration-resistant prostate cancer","volume":"85","author":"Hosseini","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2026.102570_bib0008","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/pcan.2014.28","article-title":"Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer","volume":"17","author":"McKay","year":"2014","journal-title":"Prostate Cancer and Prostatic Dis"},{"key":"10.1016\/j.clgc.2026.102570_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104241","article-title":"Blood-based liquid biopsy in advanced prostate cancer","volume":"194","author":"Giunta","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2026.102570_bib0010","article-title":"Circulating cell-free DNA: translating prostate cancer genomics into clinical care","volume":"72","author":"Tandefelt","year":"2020","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.clgc.2026.102570_bib0011","first-page":"1","article-title":"Repeat next-generation sequencing testing on progression in men with metastatic prostate cancer","volume":"8","author":"Park","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clgc.2026.102570_bib0012","unstructured":"PredicineCARE CLIA validated cfDNA assay performance specifications. https:\/\/www.predicine.com\/wp-content\/uploads\/2022\/03\/PredicineCARE2022-Final.pdf. Accessed 20 January 2022."},{"key":"10.1016\/j.clgc.2026.102570_bib0013","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jmoldx.2021.07.016","article-title":"A computational method for detecting copy number gain in clinical specimens analyzed on a next-generation sequencing platform","volume":"23","author":"Miller","year":"2021","journal-title":"J Mol Diag"},{"key":"10.1016\/j.clgc.2026.102570_bib0014","first-page":"1","article-title":"Flype: software for enabling personalized medicine","author":"Helseth","year":"2020","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.clgc.2026.102570_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.720727","article-title":"Circulating cell-free DNA-based detection of tumor suppressor gene copy number loss and its clinical implication in metastatic prostate cancer","volume":"11","author":"Dong","year":"2021","journal-title":"Frontiers Oncol"},{"key":"10.1016\/j.clgc.2026.102570_bib0016","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1200\/PO.20.00424","article-title":"Plasma cell-free DNA profiling of PTEN-PI3K-AKT pathway aberrations in metastatic castration-resistant prostate cancer","volume":"5","author":"Kwon","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.clgc.2026.102570_bib0017","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41391-021-00433-1","article-title":"PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer","volume":"25","author":"Koshkin","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2026.102570_bib0018","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"28","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102570_bib0019","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomized placebo-controlled phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2026.102570_bib0020","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102570_bib0021","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"10","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102570_bib0022","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1158\/1078-0432.CCR-24-1402","article-title":"Abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer with DNA repair defects (BRCAAway)","volume":"30","author":"Hussain","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2026.102570_bib0023","first-page":"597","article-title":"A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer","volume":"55","author":"Lang","year":"2019","journal-title":"Int J Oncol"},{"key":"10.1016\/j.clgc.2026.102570_bib0024","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2026.102570_bib0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","article-title":"Repair in prostate cancer: biology and clinical implications","volume":"71","author":"Mateo","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2026.102570_bib0026","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102570_bib0027","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102570_bib0028","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000704?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326000704?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:19:47Z","timestamp":1783941587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326000704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1558767326000704"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102570","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102570","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102570"}}